The peer-reviewed evaluation analyzed the efficacy, pharmacokinetics, and safety data obtained from over 50 studies using low-dose cannabidiol (CBD) commonly found in over-the-counter products — and exposes critical limitations and risks of these non-prescription CBD preparations at the doses administered.

The publication finds that low-dose CBD (≤2.5 mg/kg or ≤175 mg/day) — the range typical of retail products — shows little to no evidence of any biological effect or therapeutic value. The research review examined multiple pharmacokinetic studies and randomized controlled trials that included healthy volunteers and patient populations. Peak plasma exposure (Cmax) and total drug exposure (AUC) from the oral CBD formulations studied were 5–100 times lower than the therapeutic doses currently approved by regulatory authorities for medical use in epilepsy. The review also found significant drug-drug interactions with common medications including Δ9-tetrahydrocannabinol, amitriptyline, and hydromorphone, raising safety concerns for patients co-administering non-prescription CBD with other therapies.

"This comprehensive review shows that many non-prescription CBD products are administered at doses that provide exposures insufficient to achieve a therapeutic benefit," said George Warren, Ph.D., Principal Scientist at Artelo and lead author of this review. "Ineffectiveness of these CBD products may be a consequence of poor formulation strategies resulting in inadequate bioavailability. Our proprietary CBD cocrystal composition ART12.11, aims to address the therapeutic benefit challenge across multiple potential indications by increasing bioavailability when compared with CBD-alone."

The review noted that the CBD products studied alone were generally well-tolerated with no serious adverse events reported, demonstrating a favorable safety profile. However, an attractive safety profile offers no clinical value without an accompanying therapeutic benefit, particularly when treatment decisions must still account for the potential for drug-drug interactions. The analysis suggests the disappointing medical results with the CBD products studied reflect a low exposure challenge potentially from either a formulation or delivery problem — not a lack of inherent therapeutic utility in CBD itself. By improving the bioavailability of CBD, formulations such as ART12.11 may enable a therapeutic benefit to be achieved, allowing clinicians and patients to better evaluate the benefit-risk profile and make more informed treatment decisions while appropriately managing potential drug-drug interaction considerations.

The Company previously announced preclinical research that showed oral administration of ART12.11 resulted in higher plasma concentrations of CBD and its major metabolite, which is believed to be beneficial to achieve efficacy. Artelo’s research highlights the improved pharmacokinetic properties of ART12.11 over conventional CBD formulations.

"ART12.11 represents a commercially scalable and convenient tablet format to deliver CBD in appropriate and titratable doses to large patient populations and to achieve the therapeutic promise of CBD across multiple potential indications. We look forward to announcing near-term results of ongoing preclinical research with ART12.11 and advancing our patented cocrystal composition of CBD into the clinic once all the necessary preparations are concluded," concluded Dr. Warren.